Skip to main content

Website governance · effective 27 August 2026

Privacy should be legible before a conversation begins.

This notice is limited to the public NEUVIOR website and direct enquiries. It does not govern a live PHARMORIS customer service or authorise the submission of patient information.

Effective | 27 August 2026Website and enquiry scope onlyDo not submit information that identifies a patient

01 · Scope and identity

A narrow notice for a narrow processing context.

NEUVIOR Pharmaceuticals Ltd, company number SC857853, is the controller responsible for the personal information described in this website notice. Privacy enquiries can be sent to [email protected].

The notice covers information provided through public enquiry forms, direct correspondence about the website and ordinary technical records associated with serving and protecting the website. It does not govern a live PHARMORIS customer service, patient data, clinical information controlled by a customer or a future contracted deployment.

Any future product processing would require its own verified notices, contracts, roles, retention rules and data protection terms before operation.

01

Details you choose to provide

Forms may request a name, email address, organisation, role, telephone number, enquiry type, message and an affirmative consent selection.

Direct collection
02

Technical request records

Website hosting and security systems may process normal request metadata needed to deliver, protect and troubleshoot the site.

Delivery and security
03

Excluded information

Do not submit information that identifies a patient, confidential clinical records, credentials, access tokens or other sensitive operational material.

Hard boundary

02 · Purpose and handling

Information is collected to answer the request you make.

NEUVIOR uses enquiry information to route and answer the request, take steps a person asks for, keep a proportionate correspondence record, protect the website and decide whether a further conversation is relevant.

Depending on the context, the lawful basis is consent, steps requested before a possible contract, or NEUVIOR's legitimate interests in answering genuine enquiries, maintaining proportionate business records and protecting its services. Consent is used for optional future updates and can be withdrawn at any time.

Information may be handled by authorised NEUVIOR personnel and providers supporting hosting, security and email delivery. Resend receives enquiry content to deliver it to NEUVIOR. Personal information is not sold or used to create an unrelated advertising profile.

01

Retention

Enquiry records are kept only while the conversation remains relevant and for any proportionate legal, security, accounting or evidential need. Records are reviewed and deleted when those reasons no longer apply.

Need led retention
02

Service providers

Hosting, security and email providers may process information in other countries. Where required, NEUVIOR relies on an adequacy decision or appropriate contractual safeguards in the relevant provider terms. Further details can be requested by email.

Hosting, security and email
03

Automated decisions

The public enquiry flow is intended to route a message for human response. It is not presented as an automated clinical, eligibility or purchasing decision.

Human response

03 · Choice and rights

Questions and rights requests should have one direct route.

Depending on the circumstances and applicable data protection law, a person may ask about access, correction, deletion, restriction, objection, portability or withdrawal of consent. Some rights are qualified and may not apply in every case.

Send a request to [email protected] or use the governance enquiry form below. NEUVIOR may need to verify identity before disclosing or changing personal information.

If a concern is not resolved, a person can complain to the UK Information Commissioner's Office. This notice will be updated before NEUVIOR introduces a materially different use of personal information through the website.

Human decision requiredProceed only inside an evidenced and governed scope.

Governance enquiry

Raise a governance or privacy question.

Do not include data that identifies patients, confidential clinical information or special category information.

No data that identifies patients
No confidential clinical records
Human response only

If the form cannot be sent, email [email protected].

Make the next step useful

Bring the problem that needs a clearer decision.

Tell us what is stuck, what decision you need to make and what a better outcome would change. We will connect you to the most relevant NEUVIOR, PHARMORIS, media or investor route.

QUESTIONS · ANSWERED DIRECTLY

The useful answers, in one place.

Browse every question
01What is NEUVIOR?

NEUVIOR is a pharmaceutical company registered in Scotland. It is building capabilities across medicines intelligence, governed technology and longer term development. PHARMORIS is its immediate product priority.

02What does NEUVIOR build today?

NEUVIOR is developing PHARMORIS, a human-governed medicines operations system in controlled, non-production development. It is intended to connect evidence, decisions, accountable work and value review. No independent TRL, deployment, customer adoption or clinical validation is claimed.

03What is PHARMORIS by NEUVIOR?

PHARMORIS is a configurable medicines operations system under controlled development. It is designed to help authorised teams progress medicine opportunities from evidence linked to its source, through an owned ActionCase, a human decision, delivery and review.

04Who founded NEUVIOR?

Varun Sharma is the Founder, CEO and CTO of NEUVIOR and leads the company and PHARMORIS product architecture.

05Where does NEUVIOR have a presence?

NEUVIOR works across Glasgow, London and Mumbai. Glasgow is the company origin and registered Scottish base. London supports commercial activity led by the founder. Mumbai supports market engagement in India and relationships across the pharmaceutical sector. These are different forms of presence. They do not imply three registered offices or regulated facilities.